AXS-05

Effects of AXS-05, an Oral NMDA Receptor Antagonist with Multimodal Activity, on Patient Reported Depressive Symptoms in Major Depressive Disorder: Results from the GEMINI Phase 3 Double-Blind, Placebo-Controlled Trial
American Society of Clinical Psychopharmacology [ASCP], June 2021

see publication

Rapid Effects of AXS-05, an Oral NMDA Receptor Antagonist, in Major Depressive Disorder: Results from Two Randomized, Double-Blind, Controlled Trials
American Society of Clinical Psychopharmacology [ASCP], June 2021

see publication

Sustained Efficacy with Long-term Treatment with AXS-05: Results from the COMET Phase 3 Trial, a Long-term, Open-label Study Evaluating the Efficacy and Safety of AXS-05 for the Treatment of MDD
American Society of Clinical Psychopharmacology [ASCP], June 2021

see publication

Rapid Reduction in Suicidal Ideation in Patients Treated with AXS-05, an Oral NMDA Receptor Antagonist with Multimodal Activity: Results from the COMET-SI Trial
American Society of Clinical Psychopharmacology [ASCP], June 2021

see publication

Sustained Effects of AXS-05, an Oral NMDA Receptor Antagonist, in Treatment Resistant Depression Patients: Results from the COMET-TRD Trial
American Society of Clinical Psychopharmacology [ASCP], June 2021

see publication

Efficacy and Safety of AXS-05, an Oral NMDA Receptor Antagonist with Multimodal Activity, in Major Depressive Disorder: Results from the ASCEND Trial
American Psychiatric Association [APA], May 2021

see publication

Efficacy and Safety of AXS-05, an Oral NMDA Receptor Antagonist with Multimodal Activity, in Major Depressive Disorder: Results from the GEMINI Trial
American Psychiatric Association [APA], May 2021

see publication

Sustained Efficacy and Long-Term Safety of AXS-05, an Oral NMDA Receptor Antagonist, in Major Depressive Disorder: COMET Study Results
American Psychiatric Association [APA], May 2021

see publication

Rapid and Sustained Improvements in Quality of Life and Functioning with AXS-05, an Oral NMDA Receptor Antagonist, in Patients with Major Depressive Disorder
American Psychiatric Association [APA], May 2021

see publication

Rapid Effects of AXS-05, an Oral NMDA Receptor Antagonist, in Major Depressive Disorder: Results From Two Randomized, Double-Blind, Controlled Trials
Society of Biological Psychiatry [SOBP], May 2021

see publication

Efficacy and Safety of AXS-05, an Oral NMDA Receptor Antagonist with Multimodal Activity, in Major Depressive Disorder
European College of Neuropsychopharmacology [ECNP], September 2020

see publication

Efficacy and Safety of AXS-05, an Oral NMDA Receptor Antagonist with Multimodal Activity, in Major Depressive Disorder: Results from the GEMINI Phase 3, Double-Blind, Placebo-Controlled Trial (Oral Presentation)
American Society of Clinical Psychopharmacology [ASCP], May 2020

see publication

Efficacy and Safety of AXS-05, an Oral NMDA Receptor Antagonist with Multimodal Activity, in Major Depressive Disorder: Results of a Phase 2, Double-Blind, Active-Controlled Trial
American Society of Clinical Psychopharmacology [ASCP], May 2019

see publication

Efficacy and Safety of AXS-05, an Oral NMDA Receptor Antagonist with Multimodal Activity, in Major Depressive Disorder: Results of a Phase 2, Double-Blind, Active-Controlled Trial (Oral Presentation)
American Society of Clinical Psychopharmacology [ASCP], May 2019

see publication

AXS-05: A Mechanistically Novel Oral Therapeutic in Development for Neuropsychiatric Disorders
American Psychiatric Association Conference [APA], May 2019

see publication

AXS-05 for Neuropsychiatric Disorders: Scientific Rationale and Clinical Development
American Society of Clinical Psychopharmacology [ASCP], May 2018

see publication

Clinical Development of AXS-05 for Treatment Resistant Depression and Agitation Associated with Alzheimer’s Disease
American Psychiatric Association Conference [APA], May 2018

see publication

AXS-05 (Dextromethorphan/Bupropion): An Innovative Treatment in Clinical Development for Agitation Associated with Alzheimer’s Disease
Alzheimer's Association International Conference [AAIC], July 2018

see publication

Efficacy and Safety of AXS-05, a Novel Oral NMDA Receptor Antagonist with Multimodal Activity, in the Treatment of Alzheimer’s Disease Agitation: Results of the ADVANCE-1 Trial (Oral Presentation)
Clinical Trials on Alzheimer’s Disease [CTAD], November 2020

see publication

AXS-07

Treatment of Migraine Pain and Associated Symptoms with AXS-07: Results from MOVEMENT, a Long-term Efficacy and Safety Study
American Headache Society, June 2021

see publication

Efficacy and Safety of AXS-07(MoSEIC™ Meloxicam/Rizatriptan) in the Acute Treatment of Migraine: Results from the INTERCEPT Phase 3 Trial
American Headache Society, June 2021

see publication

Comparative Efficacy of AXS-07 (MoSEIC™ Meloxicam/Rizatriptan) versus Rizatriptan in the Acute Treatment of Migraine
American Headache Society, June 2021

see publication

Efficacy and Safety of AXS-07 for the Acute Treatment of Migraine: Results from the MOMENTUM (Maximizing Outcomes in Treating Acute Migraine) Phase 3 Randomized, Double-blind, Active- and Placebo-controlled Study
American Academy of Neurology [AAN] Science Highlights platform, September 2020

see publication

AXS-07 (MoSEIC™ Meloxicam/Rizatriptan): Novel Oral Therapeutic in Clinical Development for the Acute Treatment of Migraine
International Headache Society [IHC], September 2019

see publication

AXS-12

Efficacy and Safety of AXS-12 in the treatment of Narcolepsy: Results from a Phase 2, Double-Blind, Placebo-Controlled, Crossover Trial
Meeting of the Associated Professional Sleep Societies [SLEEP], August 2020

see publication